#orforpligron

Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes - PubMed In adults with early type 2 diabetes, orforglipron significantly reduced the glycated hemoglobin level over a period of 40 weeks. (Supported by Eli Lilly; ACHIEVE-1 ClinicalTrials.gov number, NCT05971...

The second @nejm.org #orforpligron paper is out.

There is no doubt that Oral GLP-1s are coming.

For #MASH, discontinuation rates will matter. 4-8% in T2DM (44w) vs. 10-17% in obesity (36w) which always seems higher.

How might our patients fare?

#liversky